Importance: There are no approved drug treatments for autosomal dominant retinitis pigmentosa, a relentlessly progressive cause of adult and childhood blindness. Objectives: To evaluate the potential efficacy and assess the safety of orally administered valproic acid (VPA) in the treatment of autosomal dominant retinitis pigmentosa. Design, Setting, and Participants: Multicenter, phase 2, prospective, interventional, placebo-controlled, double-masked randomized clinical trial. The study took place in 6 US academic retinal degeneration centers. Individuals with genetically characterized autosomal dominant retinitis pigmentosa were randomly assigned to receive treatment or placebo for 12 months. Analyses were intention-to-treat. Interventions: Oral VPA 500 mg to 1000 mg daily for 12 months or placebo. Main Outcomes and Measures: The primary outcome measure was determined prior to study initiation as the change in visual field area (assessed by the III4e isopter, semiautomated kinetic perimetry) between baseline and month 12. Results: The mean (SD) age of the 90 participants was 50.4 (11.6) years. Forty-four (48.9%) were women, 87 (96.7%) were white, and 79 (87.8%) were non-Hispanic. Seventy-nine participants (87.8%) completed the study (42 [95.5%] received placebo and 37 [80.4%] received VPA). Forty-two (46.7%) had a rhodopsin mutation. Most adverse events were mild, although 7 serious adverse events unrelated to VPA were reported. The difference between the VPA and placebo arms for mean change in the primary outcome was -150.43 degree2 (95% CI, -290.5 to -10.03; P = .035). Conclusions and Relevance: This negative value indicates that the VPA arm had worse outcomes than the placebo group. This study brings to light the key methodological considerations that should be applied to the rigorous evaluation of treatments for these conditions. This study does not provide support for the use of VPA in the treatment of autosomal dominant retinitis pigmentosa. Trial Registration: ClinicalTrials.gov Identifier: NCT01233609.
RCT Entities:
Importance: There are no approved drug treatments for autosomal dominant retinitis pigmentosa, a relentlessly progressive cause of adult and childhood blindness. Objectives: To evaluate the potential efficacy and assess the safety of orally administered valproic acid (VPA) in the treatment of autosomal dominant retinitis pigmentosa. Design, Setting, and Participants: Multicenter, phase 2, prospective, interventional, placebo-controlled, double-masked randomized clinical trial. The study took place in 6 US academic retinal degeneration centers. Individuals with genetically characterized autosomal dominant retinitis pigmentosa were randomly assigned to receive treatment or placebo for 12 months. Analyses were intention-to-treat. Interventions: Oral VPA 500 mg to 1000 mg daily for 12 months or placebo. Main Outcomes and Measures: The primary outcome measure was determined prior to study initiation as the change in visual field area (assessed by the III4e isopter, semiautomated kinetic perimetry) between baseline and month 12. Results: The mean (SD) age of the 90 participants was 50.4 (11.6) years. Forty-four (48.9%) were women, 87 (96.7%) were white, and 79 (87.8%) were non-Hispanic. Seventy-nine participants (87.8%) completed the study (42 [95.5%] received placebo and 37 [80.4%] received VPA). Forty-two (46.7%) had a rhodopsin mutation. Most adverse events were mild, although 7 serious adverse events unrelated to VPA were reported. The difference between the VPA and placebo arms for mean change in the primary outcome was -150.43 degree2 (95% CI, -290.5 to -10.03; P = .035). Conclusions and Relevance: This negative value indicates that the VPA arm had worse outcomes than the placebo group. This study brings to light the key methodological considerations that should be applied to the rigorous evaluation of treatments for these conditions. This study does not provide support for the use of VPA in the treatment of autosomal dominant retinitis pigmentosa. Trial Registration: ClinicalTrials.gov Identifier: NCT01233609.
Authors: Eliot L Berson; Bernard Rosner; Michael A Sandberg; Carol Weigel-DiFranco; Robert J Brockhurst; K C Hayes; Elizabeth J Johnson; Ellen J Anderson; Chris A Johnson; Alexander R Gaudio; Walter C Willett; Ernst J Schaefer Journal: Arch Ophthalmol Date: 2010-04
Authors: Richard G Weleber; Travis B Smith; Dawn Peters; Elvira N Chegarnov; Scott P Gillespie; Peter J Francis; Stuart K Gardiner; Jens Paetzold; Janko Dietzsch; Ulrich Schiefer; Chris A Johnson Journal: Transl Vis Sci Technol Date: 2015-04-28 Impact factor: 3.283
Authors: Maria A Parker; Dongseok Choi; Laura R Erker; Mark E Pennesi; Paul Yang; Elvira N Chegarnov; Peter N Steinkamp; Catherine L Schlechter; Claire-Marie Dhaenens; Saddek Mohand-Said; Isabelle Audo; Jose Sahel; Richard G Weleber; David J Wilson Journal: Transl Vis Sci Technol Date: 2016-10-01 Impact factor: 3.283
Authors: Anthony G Robson; Michel Michaelides; Zubin Saihan; Alan C Bird; Andrew R Webster; Anthony T Moore; Fred W Fitzke; Graham E Holder Journal: Doc Ophthalmol Date: 2007-11-06 Impact factor: 2.379
Authors: Rithambara Ramachandran; Cindy X Cai; Dongwon Lee; Benjamin C Epstein; Kirsten G Locke; David G Birch; Donald C Hood Journal: Transl Vis Sci Technol Date: 2016-05-17 Impact factor: 3.283
Authors: Jacque L Duncan; Wendi Liang; Maureen G Maguire; Isabelle Audo; Allison R Ayala; David G Birch; Joseph Carroll; Janet K Cheetham; Simona Degli Esposti; Todd A Durham; Laura Erker; Sina Farsiu; Frederick L Ferris; Elise Heon; Robert B Hufnagel; Alessandro Iannaccone; Glenn J Jaffe; Christine N Kay; Michel Michaelides; Mark E Pennesi; José-Alain Sahel Journal: Am J Ophthalmol Date: 2020-05-22 Impact factor: 5.488
Authors: Travis B Smith; Maria A Parker; Peter N Steinkamp; Albert Romo; Laura R Erker; Brandon J Lujan; Ning Smith Journal: Transl Vis Sci Technol Date: 2019-06-11 Impact factor: 3.283
Authors: Liyun Zhang; Conan Chen; Jie Fu; Brendan Lilley; Cynthia Berlinicke; Baranda Hansen; Ding Ding; Guohua Wang; Tao Wang; Daniel Shou; Ying Ye; Timothy Mulligan; Kevin Emmerich; Meera T Saxena; Kelsi R Hall; Abigail V Sharrock; Carlene Brandon; Hyejin Park; Tae-In Kam; Valina L Dawson; Ted M Dawson; Joong Sup Shim; Justin Hanes; Hongkai Ji; Jun O Liu; Jiang Qian; David F Ackerley; Baerbel Rohrer; Donald J Zack; Jeff S Mumm Journal: Elife Date: 2021-06-29 Impact factor: 8.140
Authors: Amandeep Singh Josan; Thomas M W Buckley; Laura J Wood; Jasleen K Jolly; Jasmina Cehajic-Kapetanovic; Robert E MacLaren Journal: Transl Vis Sci Technol Date: 2021-06-01 Impact factor: 3.283
Authors: Debra A Thompson; Alessandro Iannaccone; Robin R Ali; Vadim Y Arshavsky; Isabelle Audo; James W B Bainbridge; Cagri G Besirli; David G Birch; Kari E Branham; Artur V Cideciyan; Steven P Daiger; Deniz Dalkara; Jacque L Duncan; Abigail T Fahim; John G Flannery; Roberto Gattegna; John R Heckenlively; Elise Heon; K Thiran Jayasundera; Naheed W Khan; Henry Klassen; Bart P Leroy; Robert S Molday; David C Musch; Mark E Pennesi; Simon M Petersen-Jones; Eric A Pierce; Rajesh C Rao; Thomas A Reh; Jose A Sahel; Dror Sharon; Paul A Sieving; Enrica Strettoi; Paul Yang; David N Zacks Journal: Transl Vis Sci Technol Date: 2020-06-03 Impact factor: 3.283